| Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs D Charvin, R Medori, RA Hauser, O Rascol Nature Reviews Drug Discovery 17 (11), 804-822, 2018 | 267 | 2018 |
| A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition A Tarrade, C Fassier, S Courageot, D Charvin, J Vitte, L Peris, A Thorel, ... Human molecular genetics 15 (24), 3544-3558, 2006 | 218 | 2006 |
| Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation D Charvin, P Vanhoutte, C Pages, E Borelli, J Caboche Proceedings of the National Academy of Sciences 102 (34), 12218-12223, 2005 | 177 | 2005 |
| A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease E Le Poul, C Bolea, F Girard, S Poli, D Charvin, B Campo, J Bortoli, ... Journal of Pharmacology and Experimental Therapeutics 343 (1), 167-177, 2012 | 111 | 2012 |
| Mutations of SPG4 are responsible for a loss of function of spastin, an abundant neuronal protein localized in the nucleus D Charvin, C Cifuentes-Diaz, N Fonknechten, V Joshi, J Hazan, J Melki, ... Human molecular genetics 12 (1), 71-78, 2003 | 108 | 2003 |
| ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization M Kalinichev, M Rouillier, F Girard, I Royer-Urios, B Bournique, T Finn, ... Journal of Pharmacology and Experimental Therapeutics 344 (3), 624-636, 2013 | 104 | 2013 |
| Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation C Deyts, B Galan-Rodriguez, E Martin, N Bouveyron, E Roze, D Charvin, ... PloS one 4 (12), e8287, 2009 | 75 | 2009 |
| Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo D Charvin, E Roze, V Perrin, C Deyts, S Betuing, C Pagès, E Régulier, ... Neurobiology of disease 29 (1), 22-29, 2008 | 65 | 2008 |
| An m G lu4‐P ositive A llosteric M odulator A lleviates P arkinsonism in P rimates D Charvin, T Di Paolo, E Bezard, L Gregoire, A Takano, G Duvey, E Pioli, ... Movement Disorders 33 (10), 1619-1631, 2018 | 62 | 2018 |
| Expanded huntingtin activates the C-Jun N terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture M Garcia, D Charvin, J Caboche Neuroscience 127 (4), 859-870, 2004 | 51 | 2004 |
| Discovery, structure–activity relationship, and antiparkinsonian effect of a potent and brain-penetrant chemical series of positive allosteric modulators of metabotropic … D Charvin, V Pomel, M Ortiz, M Frauli, S Scheffler, E Steinberg, L Baron, ... Journal of Medicinal Chemistry 60 (20), 8515-8537, 2017 | 47 | 2017 |
| Insulin‐like growth factor‐1 and neurotrophin‐3 gene therapy prevents motor decline in an X‐linked adrenoleukodystrophy mouse model R Mastroeni, JC Bensadoun, D Charvin, P Aebischer, A Pujol, C Raoul Annals of Neurology: Official Journal of the American Neurological …, 2009 | 33 | 2009 |
| mGlu4 allosteric modulation for treating Parkinson's disease D Charvin Neuropharmacology 135, 308-315, 2018 | 30 | 2018 |
| Characterization of [11C]PXT012253 as a PET Radioligand for mGlu4 Allosteric Modulators in Nonhuman Primates A Takano, S Nag, Z Jia, M Jahan, A Forsberg, R Arakawa, P Grybäck, ... Molecular imaging and biology 21, 500-508, 2019 | 14 | 2019 |
| A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyridine core G Duvey, B Perry, E Le Poul, S Poli, B Bonnet, N Lambeng, D Charvin, ... Bioorganic & medicinal chemistry letters 23 (16), 4523-4527, 2013 | 9 | 2013 |
| A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia V Calabrese, B Picconi, N Heck, F Campanelli, G Natale, G Marino, ... Neuropharmacology 218, 109205, 2022 | 7 | 2022 |
| Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors D Charvin, B Manteau, V Pomel, F Conquet US Patent 10,017,521, 2018 | 5 | 2018 |
| Role of dopamine in Huntington's disease J Caboche, D Charvin Medecine Sciences: M/S 22 (2), 115-117, 2006 | 5* | 2006 |
| Mutations of SPG4 are responsible for a loss of function of spastin, an abundant neuronal protein localized to the nucleus D Charvin, N Fonknechten, C Cifuentes-Diaz, V Joshi, J Hazan, J Melki, ... AMERICAN JOURNAL OF HUMAN GENETICS 71 (4), 516-516, 2002 | 5 | 2002 |
| One-Pot Access to 2-Aryl-3-(Arylmethyl) Chromones MY Chang, KT Chen, YL Tsai, HY Chen Synthesis 52 (06), 861-872, 2020 | 4 | 2020 |
